Save information for later
Sign Up

Learn About Immune Thrombocytopenic Purpura (ITP)

What is the definition of Immune Thrombocytopenic Purpura (ITP)?

Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cells called platelets that are needed for normal blood clotting.

What are the causes of Immune Thrombocytopenic Purpura (ITP)?

The genetic cause of immune thrombocytopenia is unclear. This condition occurs when the body's own immune system malfunctions and attacks the body's tissues and organs (autoimmunity). Normally, the immune system produces proteins called antibodies, which attach to specific foreign particles and germs, marking them for destruction. In immune thrombocytopenia, the immune system abnormally destroys platelets and makes fewer platelets than normal. People with immune thrombocytopenia produce antibodies that attack normal platelets. The platelets are destroyed and eliminated from the body, resulting in a shortage of these cells in affected individuals. Some of these antibodies also affect the cells in the bone marrow that produce platelets (known as megakaryocytes), which leads to a decrease in platelet production, further reducing the number of platelets in the blood.

How prevalent is Immune Thrombocytopenic Purpura (ITP)?

The incidence of immune thrombocytopenia is approximately 4 per 100,000 children and 3 per 100,000 adults. In adults with immune thrombocytopenia, women are affected more often than men.

Is Immune Thrombocytopenic Purpura (ITP) an inherited disorder?

Immune thrombocytopenia and other autoimmune disorders can run in families, but the inheritance pattern is usually unknown. People with a first-degree relative (such as a parent or sibling) with immune thrombocytopenia likely have an increased risk of developing the disorder themselves.

Who are the top Immune Thrombocytopenic Purpura (ITP) Local Doctors?
Elite in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology | Pediatrics
Elite in Immune Thrombocytopenic Purpura (ITP)
Pediatric Hematology Oncology | Pediatrics
525 E 68th St # P-695, 
New York, NY 
 (4.5 mi)
Languages Spoken:
English

James Bussel is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in New York, New York. Dr. Bussel and is rated as an Elite provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Anemia, Hemolysis, and Splenectomy.

Elite in Immune Thrombocytopenic Purpura (ITP)
Hematology | Oncology | Hematology Oncology
Elite in Immune Thrombocytopenic Purpura (ITP)
Hematology | Oncology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

622 W 168th St, 
New York, NY 
 (9.5 mi)
Languages Spoken:
English
Offers Telehealth

Eun-ju Lee is a Hematologist and an Oncologist in New York, New York. Dr. Lee and is rated as an Elite provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Thrombocytopenia, Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Immune Thrombocytopenic Purpura (ITP)
Hematology Oncology | Hematology | Oncology
Experienced in Immune Thrombocytopenic Purpura (ITP)
Hematology Oncology | Hematology | Oncology

New York University

111 Broadway, 2ndf, 
New York, NY 
 (0.4 mi)
Languages Spoken:
English
Offers Telehealth

Abraham Chachoua is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Chachoua and is rated as an Experienced provider by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Lung Adenocarcinoma.

What are the latest Immune Thrombocytopenic Purpura (ITP) Clinical Trials?
A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD20 Monoclonal Antibody Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia

Summary: To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Safety and Efficacy of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Summary: To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.

Who are the sources who wrote this article ?

Published Date: June 01, 2017
Published By: National Institutes of Health